Shanghai, China, 11 May 2022 — MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, has recently received approval for its Platinium™ implantable cardioverter defibrillator (ICD) from China’s National Medical Products Administration (NMPA). The Platinium™ ICD was the first ICD product introduced by MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC).
With a rapid and largely out-of-hospital onset, malignant ventricular arrhythmias are the most common cause of sudden cardiac death. The rate of resuscitation is extremely slow as most patients miss the opportunity for proper treatment within the “golden period” of four to six minutes after onset. Currently, ICDs are recognized as the most effective treatment for sudden cardiac death. They can identify rapid ventricular arrhythmias within seconds and automatically intervene, significantly reducing the mortality of malignant ventricular arrhythmias.
Thanks to groundbreaking technologies that improve energy efficiency, the Platinium™ ICD has an expected lifespan of 13-14 years, which reduces the risks associated with frequent ICD replacement, thus providing patients with longer and more reliable life support. Meanwhile, its unique BTO and PARAD+™ algorithms can identify ventricular arrhythmia events with up to 99% specificity, thereby reducing ICD mistreatment and alleviating patient suffering. The built-in SafeR™ feature can also provide smart management of atrioventricular conduction, significantly reducing unnecessary right ventricular pacing in patients (including those with AV block), as well as lowering the risks of heart failure and atrial fibrillation due to these causes.
The approval of the Platinium™ ICD is expected to provide a more effective option for patients at high risk of sudden cardiac death. In the future, MSC will continue to improve the product portfolio in the field of heart rhythm management, providing more inclusive and accessible total medical solutions for patients with cardiac rhythm diseases.
About MicroPort® CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through its long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally.
For more information, please refer to www.microport.com
MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC) is a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK). MSC is a developer and manufacturer of medical devices in the field of cardiac rhythm management (CRM). MSC has always committed itself to the development philosophy of “Created in China” and “Made in China” to provide premium CRM products and services to patients. In the future, MSC will continue to meet the clinical needs of patients and doctors in China and offer more targeted and refined cardiology treatment and management solutions.